Edition:
United States

Spring Bank Pharmaceuticals Inc (SBPH.OQ)

SBPH.OQ on NASDAQ Stock Exchange Capital Market

13.97USD
18 May 2018
Change (% chg)

$-0.23 (-1.62%)
Prev Close
$14.20
Open
$14.13
Day's High
$14.33
Day's Low
$13.90
Volume
3,831
Avg. Vol
4,994
52-wk High
$18.93
52-wk Low
$11.04

Latest Key Developments (Source: Significant Developments)

Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial
Wednesday, 15 Nov 2017 04:30pm EST 

Nov 15 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial.Spring Bank Pharmaceuticals - ‍Inarigivir 50mg daily for 12 weeks met both primary endpoints of safety and efficacy in second cohort of achieve trial​.Spring Bank Pharmaceuticals - ‍inarigivir demonstrated a statistically significant reduction in hbv dna at week 12 compared to combined placebo group​.Spring Bank Pharma - sees Gilead initiating Phase 2 trial examining co-administration of inarigivir, vemlidy​ for infections with chronic HBV in Q1 2018.  Full Article

Spring Bank Pharmaceuticals - Q3 loss per share $0.85
Tuesday, 31 Oct 2017 06:45am EDT 

Oct 31 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals provides corporate update and reports third quarter 2017 financial and operational results.Q3 loss per share $0.85.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Spring Bank Pharmaceuticals - top-line results from second inarigivir monotherapy dosing cohort of achieve trial will be released in Q4 2017​.Spring Bank Pharmaceuticals - expects existing cash, cash equivalents, marketable securities will enable co to fund expenses, capex through 2019-end.Spring Bank - expects cash, cash equivalents, marketable securities will not be enough to fund development of inarigivir beyond Phase 2 achieve trial​.  Full Article

Spring Bank Pharmaceuticals Q4 loss per share $0.28
Wednesday, 15 Feb 2017 08:00am EST 

Spring Bank Pharmaceuticals Inc : Spring Bank Pharmaceuticals provides corporate update and reports 2016 financial and operational results .Q4 loss per share $0.28.  Full Article

Spring Bank Pharmaceuticals Q2 loss per share $0.62
Monday, 1 Aug 2016 05:14pm EDT 

Spring Bank Pharmaceuticals Inc : Q2 loss per share $0.62 .Spring bank pharmaceuticals announces second quarter 2016 financial results and recent highlights.  Full Article

BRIEF-Spring Bank Pharma Appoints Timothy Clackson To Board

* SPRING BANK PHARMACEUTICALS APPOINTS TIMOTHY CLACKSON, PH.D., TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage: